ADAM10 and cancer: Owing to its dispensable function under physiologicalconditions,ADAM8 has been considered a promising drug target for cancer therapy,whose inhibition could give fewer side effects than ADAM10/17 inhibitors.6 In particular, ADAM8 has been recently validatedas a drug target in pancreatic,7 liver,8 and breast cancer.9 Unfortunately, the development of potent and selective ADAM8 inhibitorshas been hampered by the high homology among matrix metalloproteinase(MMP) and ADAM catalytic sites.